Home
Porton Pharma Solutions Ltd. logo
Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd.

503
28
7
3.7(73)

About Company

  • Legal Name: Porton Pharma Solutions Ltd.
  • Registered country: China
  • Address: No. 7 Yuntu Road, Beibei District
  • Number of employees: 1000 - 4999
Description:

With more than 4,300 employees and 17 operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical and biotech companies with innovative, reliable, end-to-end process R&D and GMP manufacturing services spanning small molecules, TIDES, biologics and conjugates (ADCs, AOCs, DACs, PDCs, RDCs and others), as well as advanced therapy medicinal products. Committed to a customer-centric approach, the company has been recognized through industry awards for process innovation, supply chain performance, and compliance with global quality and EHS standards.

Business Activities

Contract & Outsourcing Services

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Biopharmaceutical Products

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Contract Research Organisations Services (CROs)

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Biopharmaceutical Services

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Laboratory & Analytical Services

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Innovator APIs

Service ProviderContract ManufacturerAPI ManufacturerTesting LaboratoryClinical Trial OrganizationRegulatory Consultant

Certifications

FDA

Other

GMP

ISO

Proofs

CPHI & PMEC China 2026
CPHI & PMEC China 2026
06/2026 – 06/2026

CPHI & PMEC China 2026

Location
Shanghai New International Expo Center
Filters:
Sort by:

    No comments available.